ArticleDiscover oncology2025
The multi-omics analysis identifies a novel endoplasmic reticulum stress and immune related genes signature in lung adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD), a prevalent and aggressive malignancy, necessitates improved prognostic tools and therapeutic insights. While endoplasmic reticulum stress (ERS) and tumor-immune interactions are recognized as key cancer hallmarks, their combined prognostic potential in LUAD remains insufficiently explored.
methodsUtilizing transcriptomic and clinical data from the TCGA-LUAD cohort, we developed an ERS-immune prognostic signature through Least Absolute Shrinkage and Selection Operator algorithm. A clinical nomogram integrating risk scores with established prognostic factors was established. Tumor microenvironment characteristics were evaluated using the CIBERSORT and ESTIMATE algorithm. The changes following the CR2 gene knockdown in NSCLC cells were evaluated through CCK-8 assay and Transwell assays.
resultsThe 10-gene signature effectively stratified patients into distinct risk groups with significant survival differences. The nomogram demonstrated enhanced predictive accuracy compared to traditional staging systems. High-risk patients exhibited immunosuppressive features. CR2 knockdown significantly reduced cellular proliferation and inhibited metastatic capacity.
conclusionThis integrated ERS-immune signature provides clinically relevant prognostic stratification and reveals potential therapeutic vulnerabilities in LUAD, offering a framework for personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.